Author

F. Roedel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

F. Rothweiler· 2 shared J. Cinatl· 2 shared M. Michaelis· 2 shared M. N. Wass· 2 shared S. Hehlgans· 2 shared Y. Voges· 2 shared A. Moroni· 1 shared A. Nist· 1 shared

Activity by Year

2020-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

F. Rothweiler

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

X-ray Irradiation activates immune response in human T-lymphocytes by eliciting a Ca2+ signaling cascade

G. Thiel, D. H. Tandl, T. Sponagel, S. Fuck, T. Smit, S. Hehlgans, B. Jakob, C. Fournier, F. Roedel, B. Roth, A. Moroni

The paper shows X-ray irradiation triggers a Ca2+ signaling cascade in T-lymphocytes, leading to immune activation through NFAT nuclear translocation.

bioRxiv · Nov 13, 2020Biophysics

Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting

M. Michaelis, M. N. Wass, I. Reddin, Y. Voges, F. Rothweiler, S. Hehlgans, J. Cinatl, M. Mernberger, A. Nist, T. Stiewe, F. Roedel, J. Cinatl

The paper investigates drug-induced heterogeneity in cancer cell lines and identifies biomarkers for acquired resistance to YM155.

bioRxiv · Feb 13, 2020Pharmacology & Toxicology

Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines

M. Michaelis, Y. Voges, F. Rothweiler, F. Weipert, A. Zhia-Amad, J. Cinatl, A. von Deimling, F. Westermann, F. Roedel, M. N. Wass, J. Cinatl

This study tests YM155 in 101 neuroblastoma cell lines, revealing ABCB1 and ABCC1 as mediators of resistance and highlighting cross-resistance differences between drug-adapted lines.

bioRxiv · Jan 27, 2020Pharmacology & Toxicology